<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3894">
  <stage>Registered</stage>
  <submitdate>8/04/2013</submitdate>
  <approvaldate>8/04/2013</approvaldate>
  <nctid>NCT01831544</nctid>
  <trial_identification>
    <studytitle>A Clinical Trial to Evaluate the HeartWare MVAD® System (MVAdvantage)</studytitle>
    <scientifictitle>Multi Center, Prospective, Non-Randomized, Single-Arm Trial Evaluating the Clinical Safety and Performance Of the HeartWare MVAD® System For the Treatment of Advanced Heart Failure</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HW-MVAD-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - HeartWare MVAD® System

Experimental: MVAD® Pump - Implant of HeartWare MVAD® System


Treatment: devices: HeartWare MVAD® System
The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival - The primary endpoint is survival at 6 months presented as a simple proportion</outcome>
      <timepoint>Six month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Survival - Survival at 24 months presented as a simple proportion (defined like the primary endpoint)</outcome>
      <timepoint>Two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survival - Overall Survival (Time to Death)</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of major bleeding - Incidence of major bleeding, per INTERMACS definition</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of all device failures and device malfunctions - Incidence of all device failures and device malfunctions per INTERMACS definition</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of major infection - Incidence of major infection, per INTERMACS definition</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of neurological dysfunction - Incidence of neurological dysfunction per INTERMACS definition</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Status change, as measured by KCCQ and EuroQol EQ-5D-5L - Health Status change, as measured by KCCQ and EuroQol EQ-5D-5L</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional status change, as measured by NYHA and 6-minute walk - Functional status change, as measured by NYHA and 6-minute walk</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency and rates of adverse events(AEs) - Frequency and rates of adverse events(AEs) throughout VAD support per INTERMACS Definition</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of operative time and initial hospital stay - Length of operative time and initial hospital stay</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Re-Hospitalizations - Re-Hospitalizations, excluding planned procedures</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Transplantations - Transplantations</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Explants - Explants</outcome>
      <timepoint>Six month and two years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Must be =18 years of age at consent

          2. Subjects with advanced heart failure symptoms (Class IIIB or IV) who meet one of the
             following):

               1. on optimal medical management including dietary salt restriction and diuretics,
                  for at least 45 out of the last 60 days and are failing to respond; or

               2. in Class III or Class IV heart failure for at least 14 days and dependent on
                  intra-aortic balloon pump (IABP) and/or inotropes.

          3. Left ventricular ejection fraction =25%.

          4. Female subjects of childbearing potential must agree to use adequate contraceptive
             precautions (defined as oral contraceptives, intrauterine devices, surgical
             contraceptives or a combination of condom and spermicide) for the duration of the
             study.

          5. The subject has signed the informed consent form.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Body Mass Index (BMI) &gt; 47.

          2. Body Surface Area (BSA) &lt; 1.0 m2.

          3. Partial or full mechanical circulatory support within thirty days of implant.

          4. Existence of any ongoing mechanical circulatory support (MCS) other than an
             intra-aortic balloon pump (IABP) or TandemHeart PTVA®.

          5. Prior cardiac transplant or cardiomyoplasty.

          6. History of confirmed, untreated abdominal or thoracic aortic aneurysm (diameter &gt; 5
             cm).

          7. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave
             changes on the electrocardiogram (ECG), diagnostic biomarkers, ongoing pain and
             hemodynamic abnormalities.

          8. On ventilator support for &gt; 72 hours within the four days immediately prior to
             implant.

          9. Pulmonary embolus within three weeks of implant as documented by computed tomography
             (CT) scan or nuclear scan.

         10. Symptomatic cerebrovascular disease, stroke within 180 days of implant or &gt; 80%
             stenosis of carotid or cranial vessels in the absence of confirmed collateral
             circulation

         11. Uncorrected moderate to severe aortic insufficiency.

         12. Severe right ventricular failure as defined by the anticipated need for extracorporeal
             membrane oxygenation (ECMO) at the time of screening.

         13. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and
             laboratory testing, including but not limited to, continued positive cultures,
             elevated temperature and white blood cell (WBC) count, hypotension, tachycardia,
             generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment.

         14. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count &lt;
             75,000, International Normalized Ratio (INR) &gt; 2.0 or Partial Thromboplastin Time
             (PTT) &gt; 2.5 times control in the absence of anticoagulation therapy).

         15. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or
             postoperative therapy that the investigator may administer based upon the subject's
             health status.

         16. Serum creatinine &gt; 3.0 mg/dL within 72 hours of implant or requiring dialysis.

         17. Specific liver enzymes [Aspartate Aminotransferase (AST) (SGOT), and Alanine
             Aminotransferase (ALT) (SGPT)] &gt; 3 times upper limit of normal within 72 hours of
             implant.

         18. A total bilirubin &gt; 3 mg/dL within 72 hours of implant, or biopsy proven liver
             cirrhosis or portal hypertension.

         19. Pulmonary vascular resistance (PVR) is demonstrated to be unresponsive to
             pharmacological manipulation.

         20. Subjects with a mechanical heart valve.

         21. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease,
             obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or
             restrictive cardiomyopathy.

         22. History of severe COPD or severe restrictive lung disease (e.g. FEV1 &lt; 50% predicted
             value).

         23. Participation in any other trial involving investigational drugs or devices within 4
             weeks prior to screening and last visit of the trial.

         24. Severe illness, other than heart disease, which would limit survival to &lt; 3 years.

         25. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities.

         26. Pregnancy and breast feeding.

         27. Psychiatric disease, irreversible cognitive dysfunction or psychosocial issues that
             are likely to impair compliance with the CIP and LVAD.

         28. Subject unwilling or unable to comply with trial requirements.

         29. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of
             the investigator.

         30. Employees of the investigator or trial site, with direct involvement in this trial or
             other trials under the direction of the investigator or trial site, as well as family
             members or employees of the investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>15/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>11</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>St. Vincents Hospital - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Oeynhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle upon Tyne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Papworth Everard</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>HeartWare, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This multi-center, prospective, non-randomized, single-arm trial will investigate the safety
      and performance of the HeartWare® Miniaturized Ventricular Assist Device (MVAD®) system over
      24 months in subjects with advanced heart failure</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01831544</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>